What if...
We define cancer as a disease of evolutionary origin?
What if...
We accept that successful treatment of cancer will require dealing with ecology and evolution of tumors?
What if...
We can learn from mother Nature how it uses evolution to solve the biological problems and use this knowledge to develop entirely new class of drugs?
Aveta Biomics is pioneering a way to unlock the power of nature-inspired drugs. Our platform, powered by insights into evolutionary biology, creates the next generation of first-in-class immune-oncology drugs intended to provide a durable response to cancer patients.

Parag G. Mehta, PhD
Chief Executive Officer

Selda Samakoglu, MD, PhD
Chief Medical Officer

Luis Z Avila, PhD
Chief Scientific Officer

Martina Molsbergen
Chief Business Officer

Robert Charnas, PhD
Senior Vice President, Regulatory Affairs

Prof. S. P. Kothari
Board Director

David Page
Board Director

Parag G. Mehta, PhD
Board Director

Peter Dolan
Board Director

Bharat Tewarie, MD, MBA
Board Director

Thomas Rudolph, MD
Board Director

Anastasia Tousimis, MD, FACS, MBA
Scientific and Medical Advisor

Andrew Sikora, MD, PhD
Scientific and Medical Advisor

Joseph A Califano III, MD
Scientific and Medical Advisor

Jonathan Schonfeld, MD, MPH
Scientific and Medical Advisor

Eugene I. Shakhnovich, PhD
Scientific Advisor

Daniel Hartl, PhD
Scientific Advisor

Ajay Gupta
Executive Advisor

Jan Hagemeier
Executive Advisor